Delivery Order SPE2DB20D2104-SPE2DB25FMTKP
- Not listed
- The Defense Logistics Agency (DLA) awarded a $12,851.51 delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for the supply of Xifaxan 550 mg tablets (60-count). This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The order is scheduled for completion by September 24, 2025, and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) with a contract value of $4,557.98. This firm fixed-price delivery order, with an ultimate completion date of July 30, 2025, represents a non-set-aside, competitively awarded procurement supporting federal medical supply needs. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) under a firm fixed-price contract valued at $2,392.21. The order carries an ultimate completion date of September 9, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's...
- The Defense Logistics Agency awarded a $2,053.56 delivery order to AmerisourceBergen Drug Corp for Xifaxan 550 mg tablets (60-count) on May 30, 2025, with an ultimate completion date of June 2, 2025. This firm fixed price, non-set-aside contract is being performed in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order valued at $18,007.34 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) under a firm fixed price contract. This non-competitive delivery order, issued on September 5, 2025, with an ultimate completion date of September 8, 2025, represents a routine pharmaceutical procurement executed through the company's existing Indefinite Delivery Contract with DLA Troop Support Medical. AmerisourceBergen, a major...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) at a ceiling value of $1,846.22. This firm fixed-price delivery order, which is not set-aside, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The order will be fulfilled from the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Xifaxan 550 mg tablets in a quantity of 60 units, with a ceiling value of $16,598.12. This firm fixed-price delivery order is part of a competitive procurement with no set-aside designation and is scheduled for completion by September 10, 2025. The place of performance is AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a delivery order valued at $7,847.44 to AmerisourceBergen Drug Corp for 60 tablets of Xifaxan 550 mg on June 4, 2025, with completion expected by June 5, 2025. This non-competitive delivery order is priced on a firm fixed-price basis and represents a child contract under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $4,215.61 to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Xifaxan 550 mg tablets (60-count units). This is a firm fixed price delivery order with an ultimate completion date of September 16, 2025, performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award involved no set-aside designation, indicating it was competitively awarded through open competition. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of Xifaxan 550 mg tablets in unit dose packaging (60 units) with a contract ceiling value of $8,588.18. This competitively awarded, firm fixed price delivery order is scheduled for completion by September 26, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMTKPDelivery Order
The Defense Logistics Agency awarded a $12,163.66 delivery order to AmerisourceBergen Drug Corp on June 16, 2025, for the supply of Xifaxan 550 mg tablets (60-count units). This competitively awarded, firm fixed-price delivery order is scheduled for completion by June 17, 2025, with performance at the contractor's Conshohocken, Pennsylvania location. The award carries no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to compete in the federal pharmaceutical procurement market. This delivery order represents a task issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement through December 2026 that serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. As a major pharmaceutical distributor and critical federal medical supply vendor, AmerisourceBergen maintains an extensive portfolio of pharmaceutical products and medical supplies supporting the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's federal contract performance demonstrates consistent success in fulfilling competitively awarded orders across a broad spectrum of therapeutic domains, positioning it as a key supplier within the DLA's medical supply chain infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.2k | 6/16/25 |